What is the level of liabilities of Radiopharm Theranostics this year?
Radiopharm Theranostics has a debt balance of 43.91 M AUD this year.
In 2024, Radiopharm Theranostics's total liabilities amounted to 43.91 M AUD, a 115.07% difference from the 20.42 M AUD total liabilities in the previous year.
Radiopharm Theranostics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Radiopharm Theranostics's financial stability, operational efficiency, and long-term viability.
By comparing Radiopharm Theranostics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Radiopharm Theranostics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Radiopharm Theranostics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Radiopharm Theranostics has a debt balance of 43.91 M AUD this year.
The liabilities of Radiopharm Theranostics have increased by 115.07% increased compared to the previous year.
High liabilities can pose a risk for investors of Radiopharm Theranostics, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Radiopharm Theranostics has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Radiopharm Theranostics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Radiopharm Theranostics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Radiopharm Theranostics include investments, acquisitions, operating costs, and sales development.
The liabilities of Radiopharm Theranostics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Radiopharm Theranostics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Radiopharm Theranostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Radiopharm Theranostics is expected to pay a dividend of 0 AUD.
The current dividend yield of Radiopharm Theranostics is .
Radiopharm Theranostics pays a quarterly dividend. This is distributed in the months of .
Radiopharm Theranostics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
Radiopharm Theranostics is assigned to the 'Health' sector.
To receive the latest dividend of Radiopharm Theranostics from 10/5/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
The last dividend was paid out on 10/5/2024.
In the year 2023, Radiopharm Theranostics distributed 0 AUD as dividends.
The dividends of Radiopharm Theranostics are distributed in AUD.
Our stock analysis for Radiopharm Theranostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Radiopharm Theranostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.